LindaRDuskaMD

Obstetrics & Gynecology • Charlottesville, VA

Gynecologic Oncology, Hospice & Palliative Medicine

Professor of Obstetrics & Gynecology, University VA School of Medicine

Join to view full profile

Dr. Duska is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Duska's full profile

Already have an account?

Office
1240 Lee St
Charlottesville, VA 22908
Phone+1 434-924-9333

Fax+1 434-244-7526

Education & Training

Massachusetts General HospitalFellowship, Gynecologic Oncology, 1995 - 1998
Johns Hopkins UniversityResidency, Obstetrics and Gynecology, 1991 - 1995
New York University School of MedicineClass of 1991

Certifications & Licensure

VA State Medical License 2008 - 2026
FL State Medical License 2019 - 2021
MA State Medical License 1995 - 2012
American Board of Internal Medicine Hospice and Palliative Medicine
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2012-2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
America's Top Doctors for Cancer Castle Connolly, 2011-2013
Fellow (FACS) American College of Surgeons
Fellow (FACOG) American Congress of Obstetricians and Gynecologists
Join now to see all

Clinical Trials

Cetuximab, Cisplatin, and Radiotherapy in Women With Locally Advanced Cervical Carcinoma Start of enrollment: 2006 Feb 01
Unknown status
Phase 2
Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2009 Oct 28
Completed
Phase 1
Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Start of enrollment: 2010 Apr 05
Completed
Phase 1
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy Start of enrollment: 2010 Nov 01
Completed
Phase 2
A Prospective Trial of COXEN Chemotherapy Prediction Start of enrollment: 2010 Oct 01
Withdrawn
Not Applicable
Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer Start of enrollment: 2012 Jan 01
Completed
Early Phase 1
A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer Start of enrollment: 2012 Sep 01
Completed
Phase 2
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer Start of enrollment: 2013 Apr 01
Completed
Phase 3
Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer Start of enrollment: 2017 Oct 11
Completed
Early Phase 1
Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2018 Oct 12
ACTIVE_NOT_RECRUITING
PHASE2
A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208) Start of enrollment: 2019 Mar 20
Completed
Phase 2
Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer Start of enrollment: 2019 May 14
Active, not recruiting
Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer Start of enrollment: 2021 Feb 22
ACTIVE_NOT_RECRUITING
PHASE3
Join now to see all

Publications & Presentations

PubMed

Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial).
Husam A Alqaisi, David E Cohn, Jing-Yi Chern, Linda R Duska, Andrea Jewell
Clinical Cancer Research. 2025-03-17
Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometrial cancer: A real-world endometrial cancer ...
Paulina J Haight, Marilyn Sanchez, Samantha M Thomas, Carson Smitherman, Casey Cosgrove
Gynecologic Oncology. 2025-02-21
Update on safety and feasibility of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer.
Linda R Duska, Gina R Petroni, Premal H Thaker, Erin K Crane, Laura L Holman
Cancer. 2025-02-15

Lectures

Surgery Is Critical to a Multidisciplinary Approach to Ovarian Cancer
ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019

Press Mentions

New Standard of Care for Cervical Cancer: Survival Data Back Pembro RegimenMarch 18th, 2025
Pembrolizumab-CRT: The New Standard of Care in Locally Advanced Cervical Cancer?March 15th, 2025
Pembrolizumab plus Chemotherapy Regimen Yields Clinically Positive Outcomes for Treatment of Locally Advanced Cervical CancerMarch 14th, 2025
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member
American College of Obstetricians and Gynecologists
Fellow
American College of Surgeons - ACS
Member